2020 journal article
Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis
NATURE COMMUNICATIONS, 11(1).
MeSH headings : Administration, Inhalation; Alveolar Epithelial Cells / drug effects; Alveolar Epithelial Cells / metabolism; Alveolar Epithelial Cells / pathology; Animals; Apoptosis / drug effects; Bleomycin / toxicity; Cell Proliferation; Disease Models, Animal; Exosomes / metabolism; Exosomes / transplantation; Humans; Idiopathic Pulmonary Fibrosis / chemically induced; Idiopathic Pulmonary Fibrosis / metabolism; Idiopathic Pulmonary Fibrosis / pathology; Idiopathic Pulmonary Fibrosis / therapy; Lung / cytology; Lung / metabolism; Lung Injury / chemically induced; Lung Injury / metabolism; Lung Injury / pathology; Lung Injury / therapy; Mesenchymal Stem Cells / metabolism; Mice; Myofibroblasts / cytology; Proteomics; Silicon Dioxide / toxicity; Spheroids, Cellular / metabolism
TL;DR:
It is shown that the secretome and exosomes of lung spheroid cells is effective as inhalation treatment in rodent models of lung injury and fibrosis and superior to the counterparts derived from mesenchymal stem cells.
(via Semantic Scholar)
open access via www.nature.com (publisher PDF)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science; OpenAlex)
Source: Web Of Science
Added: March 23, 2020
AbstractIdiopathic pulmonary fibrosis (IPF) is a fatal and incurable form of interstitial lung disease in which persistent injury results in scar tissue formation. As fibrosis thickens, the lung tissue loses the ability to facilitate gas exchange and provide cells with needed oxygen. Currently, IPF has few treatment options and no effective therapies, aside from lung transplant. Here we present a series of studies utilizing lung spheroid cell-secretome (LSC-Sec) and exosomes (LSC-Exo) by inhalation to treat different models of lung injury and fibrosis. Analysis reveals that LSC-Sec and LSC-Exo treatments could attenuate and resolve bleomycin- and silica-induced fibrosis by reestablishing normal alveolar structure and decreasing both collagen accumulation and myofibroblast proliferation. Additionally, LSC-Sec and LSC-Exo exhibit superior therapeutic benefits than their counterparts derived from mesenchymal stem cells in some measures. We showed that an inhalation treatment of secretome and exosome exhibited therapeutic potential for lung regeneration in two experimental models of pulmonary fibrosis.